145 related articles for article (PubMed ID: 38211909)
21. Ganoderma microsporum immunomodulatory protein as an extracellular epidermal growth factor receptor (EGFR) degrader for suppressing EGFR-positive lung cancer cells.
Hua WJ; Yeh H; Lin ZH; Tseng AJ; Huang LC; Qiu WL; Tu TH; Wang DH; Hsu WH; Hwang WL; Lin TY
Cancer Lett; 2023 Dec; 578():216458. PubMed ID: 37865161
[TBL] [Abstract][Full Text] [Related]
22. Targeting PI3Kα overcomes resistance to KRas
Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH
Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
[TBL] [Abstract][Full Text] [Related]
24. First-in-Humans PET Imaging of
Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J
J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842
[TBL] [Abstract][Full Text] [Related]
25. Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents.
Li L; Zhao H; Peng X; Liu J; Mai R; Chen J; Lin L; Chen T; Yan J; Shi J; Chen J
Bioorg Med Chem; 2022 Oct; 71():116962. PubMed ID: 35987104
[TBL] [Abstract][Full Text] [Related]
26. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors.
Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM
Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229
[TBL] [Abstract][Full Text] [Related]
27. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
Khan S; Budamagunta V; Zhou D
Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
[TBL] [Abstract][Full Text] [Related]
28. Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.
Riquelme E; Behrens C; Lin HY; Simon G; Papadimitrakopoulou V; Izzo J; Moran C; Kalhor N; Lee JJ; Minna JD; Wistuba II
Cancer Res; 2016 Feb; 76(3):675-85. PubMed ID: 26676756
[TBL] [Abstract][Full Text] [Related]
29. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
[TBL] [Abstract][Full Text] [Related]
30. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models.
Nakayama A; Nagashima T; Nishizono Y; Kuramoto K; Mori K; Homboh K; Yuri M; Shimazaki M
Br J Cancer; 2022 Mar; 126(5):744-753. PubMed ID: 34795410
[TBL] [Abstract][Full Text] [Related]
31. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
32. Pixantrone confers radiosensitization in KRAS mutated cancer cells by suppression of radiation-induced prosurvival pathways.
Tripathi P; Soni R; Antra ; Tandon V
Free Radic Biol Med; 2022 Sep; 190():351-362. PubMed ID: 35970251
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic KRAS
Mugarza E; van Maldegem F; Boumelha J; Moore C; Rana S; Llorian Sopena M; East P; Ambler R; Anastasiou P; Romero-Clavijo P; Valand K; Cole M; Molina-Arcas M; Downward J
Sci Adv; 2022 Jul; 8(29):eabm8780. PubMed ID: 35857848
[TBL] [Abstract][Full Text] [Related]
34. Cell Type-specific Adaptive Signaling Responses to KRAS
Solanki HS; Welsh EA; Fang B; Izumi V; Darville L; Stone B; Franzese R; Chavan S; Kinose F; Imbody D; Koomen JM; Rix U; Haura EB
Clin Cancer Res; 2021 May; 27(9):2533-2548. PubMed ID: 33619172
[TBL] [Abstract][Full Text] [Related]
35. Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer.
Yu X; Liu J; Qiu H; Hao H; Zhu J; Peng S
Bosn J Basic Med Sci; 2021 Apr; 21(2):198-207. PubMed ID: 32530390
[TBL] [Abstract][Full Text] [Related]
36. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
37. The KRAS
Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
[TBL] [Abstract][Full Text] [Related]
38. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
[TBL] [Abstract][Full Text] [Related]
39. GMI, an immunomodulatory protein from Ganoderma microsporum, induces autophagy in non-small cell lung cancer cells.
Hsin IL; Ou CC; Wu TC; Jan MS; Wu MF; Chiu LY; Lue KH; Ko JL
Autophagy; 2011 Aug; 7(8):873-82. PubMed ID: 21490426
[TBL] [Abstract][Full Text] [Related]
40. Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.
Caiola E; Brunelli L; Marabese M; Broggini M; Lupi M; Pastorelli R
Oncotarget; 2016 Aug; 7(32):51462-51472. PubMed ID: 27283493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
